Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CYTOKINETICS, INC.
09/19 CYTOKINETICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
09/19 Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at t..
09/09 Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at t..
09/08 CYTOKINETICS INC : Other Events (form 8-K)
09/08 Cytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Enterin..
09/01 CYTOKINETICS INC : Entry into a Material Definitive Agreement, Other Events, Fin..
09/01DJAMGEN : Cytokinetics Heart Drug Moves to Late-Stage Development
09/01DJAMGEN : Acquires Rights to Multiple Myeloma Therapy From Boehringer
09/01 Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Deve..
09/01 CYTOKINETICS : Enrolls 700 ALS Patients in Phase 3 Study of Tirasemtiv
More news
Sector news : Bio Therapeutic Drugs
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Therapeutic Drugs
Financials ($)
Sales 2016 30,1 M
EBIT 2016 -48,9 M
Net income 2016 -51,2 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 11,5x
Capi. / Sales 2017 10,6x
Capitalization 348 M
More Financials
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,0 $
Spread / Average Target 128%
Consensus details
EPS Revisions
More Estimates Revisions
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.7.68%130 813
GILEAD SCIENCES, INC.-19.59%107 381
More Results